Chemours (CC) Faces A Lawsuit, Is The Stock Still Cheap?

Gainey McKenna & Egleston has launched a securities class action against Chemours (CC) in the District of Delaware, challenging disclosures around Opteon demand and 2026 financial guidance during the February to August 2026 period.

Chemours shares trade at US$13.61, with the 30 day share price return down 9.45% and the 90 day move down 24.89%, while the year to date share price return remains up 11.10% and the 1 year total shareholder return is 10.80%, set against much weaker 3 and 5 year total shareholder returns that indicate longer term momentum is still fading.

Contrast Chemours' legal and demand pressures with other materials stocks that screen well on cash flow strength and valuation by scanning our hand picked 29 high quality undervalued stocks list today.

Chemours now trades well below recent levels after the lawsuit headlines and guidance questions. Is that a reasonable entry for patient buyers or does the risk case argue for waiting on clearer valuation support first?

Most Popular Narrative: 27% Undervalued

Chemours is framed by the most followed narrative as undervalued, with a fair value estimate of $18.56 against the last close at $13.61, putting the lawsuit headlines against a materially higher long term cash flow story.

Acceleration in regulatory-driven adoption of low global warming potential (GWP) refrigerants is boosting sustained demand for Chemours' Opteon franchise. Recent strong net sales and high margins signal that continued market share gains and capacity expansions will drive robust revenue and EBITDA growth through and beyond the 2025 and 2026 transition periods.

See why 13 investors see Chemours as 27% undervalued.

Result: Fair Value of $18.56 (UNDERVALUED)

Still, Chemours faces two clear swing factors: any setback on PFAS settlements or weaker TiO2 pricing could quickly challenge the current undervaluation thesis.

Find out about the key risks to this Chemours narrative.

Next Steps

Mixed headlines and split sentiment around Chemours do not have to dictate your stance. Take a close look at the data, weigh the 1 or more risks against the 1 or more rewards, and then review the 3 key rewards and 2 important warning signs.

Looking for more Chemours alternatives and fresh ideas?

If Chemours has sharpened your focus on risk and reward, do not stop here. Use the Simply Wall Street Screener to surface other opportunities that might suit your approach.

• Target potential mispricings by scanning a concise 20 high quality undiscovered gems that many investors may be overlooking.
• Prioritise resilience by working through a 31 resilient stocks with low risk scores that keeps overall risk scores front and centre.
• Anchor your watchlist around balance sheet strength by checking a list of solid balance sheet and fundamentals (25 results) before sentiment moves on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com